TH17 cells and corticosteroid insensitivity in severe asthma

Yan Xie, Peter W. Abel, Thomas B. Casale, Yaping Tu

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Asthma is classically described as having either a type 2 (T2) eosinophilic phenotype or a non-T2 neutrophilic phenotype. T2 asthma usually responds to classical bronchodilation therapy and corticosteroid treatment. Non-T2 neutrophilic asthma is often more severe. Patients with non-T2 asthma or late-onset T2 asthma show poor response to the currently available anti-inflammatory therapies. These therapeutic failures result in increased morbidity and cost associated with asthma and pose a major health care problem. Recent evidence suggests that some non-T2 asthma is associated with elevated TH17 cell immune responses. TH17 cells producing Il-17A and IL-17F are involved in the neutrophilic inflammation and airway remodeling processes in severe asthma and have been suggested to contribute to the development of subsets of corticosteroid-insensitive asthma. This review explores the pathologic role of TH17 cells in corticosteroid insensitivity of severe asthma and potential targets to treat this endotype of asthma.

Original languageEnglish (US)
Pages (from-to)467-479
Number of pages13
JournalJournal of Allergy and Clinical Immunology
Issue number2
StatePublished - Feb 2022

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'TH17 cells and corticosteroid insensitivity in severe asthma'. Together they form a unique fingerprint.

Cite this